123 related articles for article (PubMed ID: 38882462)
1. Letermovir Primary Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients: Real-Life Data from a University Hospital in Argentina.
Herrera F; Torres D; Querci M; Rearte AN; Temporiti E; Riera L; Duarte P; Videla C; Bonvehí P
Mediterr J Hematol Infect Dis; 2024; 16(1):e2024039. PubMed ID: 38882462
[TBL] [Abstract][Full Text] [Related]
2. Clinical "real-world" experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients.
Anderson A; Raja M; Vazquez N; Morris M; Komanduri K; Camargo J
Clin Transplant; 2020 Jul; 34(7):e13866. PubMed ID: 32242979
[TBL] [Abstract][Full Text] [Related]
3. Refractory and Resistant Cytomegalovirus After Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis Era.
Sassine J; Khawaja F; Shigle TL; Handy V; Foolad F; Aitken SL; Jiang Y; Champlin R; Shpall E; Rezvani K; Ariza-Heredia EJ; Chemaly RF
Clin Infect Dis; 2021 Oct; 73(8):1346-1354. PubMed ID: 33830182
[TBL] [Abstract][Full Text] [Related]
4. Cytomegalovirus Infection after Allogeneic Hematopoietic Cell Transplantation under 100-Day Letermovir Prophylaxis: A Real-World 1-Year Follow-Up Study.
Nho D; Lee R; Cho SY; Lee DG; Kim EJ; Park S; Lee SE; Cho BS; Kim YJ; Lee S; Kim HJ
Viruses; 2023 Sep; 15(9):. PubMed ID: 37766290
[TBL] [Abstract][Full Text] [Related]
5. Letermovir Prophylaxis and Cytomegalovirus Reactivation in Adult Hematopoietic Cell Transplant Recipients with and without Acute Graft Versus Host Disease.
Wolfe D; Zhao Q; Siegel E; Puto M; Murphy D; Roddy J; Efebera Y; Tossey J
Cancers (Basel); 2021 Nov; 13(21):. PubMed ID: 34771734
[TBL] [Abstract][Full Text] [Related]
6. A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation.
Ljungman P; Schmitt M; Marty FM; Maertens J; Chemaly RF; Kartsonis NA; Butterton JR; Wan H; Teal VL; Sarratt K; Murata Y; Leavitt RY; Badshah C
Clin Infect Dis; 2020 Apr; 70(8):1525-1533. PubMed ID: 31179485
[TBL] [Abstract][Full Text] [Related]
7. Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data.
Derigs P; Radujkovic A; Schubert ML; Schnitzler P; Schöning T; Müller-Tidow C; Hegenbart U; Schönland SO; Luft T; Dreger P; Schmitt M
Ann Hematol; 2021 Aug; 100(8):2087-2093. PubMed ID: 33270162
[TBL] [Abstract][Full Text] [Related]
8. Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study.
Chemaly RF; El Haddad L; Winston DJ; Rowley SD; Mulane KM; Chandrasekar P; Avery RK; Hari P; Peggs KS; Kumar D; Nath R; Ljungman P; Mossad SB; Dadwal SS; Blanchard T; Shah DP; Jiang Y; Ariza-Heredia E
Clin Infect Dis; 2020 Dec; 71(9):2365-2374. PubMed ID: 32076709
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of letermovir for cytomegalovirus prophylaxis in allogeneic hematopoietic stem cell transplant recipients: A global systematic review.
Sepassi A; Saunders IM; Bounthavong M; Taplitz RA; Logan C; Watanabe JH
J Am Pharm Assoc (2003); 2023; 63(4):1138-1149. PubMed ID: 37207713
[TBL] [Abstract][Full Text] [Related]
10. Letermovir for Prevention of Cytomegalovirus Reactivation in Haploidentical and Mismatched Adult Donor Allogeneic Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.
Lin A; Flynn J; DeRespiris L; Figgins B; Griffin M; Lau C; Proli A; Devlin SM; Cho C; Tamari R; Jakubowski AA; Papadopoulos EB; Giralt SA; Perales MA; Seo SK; Shaffer B
Transplant Cell Ther; 2021 Jan; 27(1):85.e1-85.e6. PubMed ID: 33053449
[TBL] [Abstract][Full Text] [Related]
11. Effective CMV prophylaxis with high-dose valaciclovir in allogeneic hematopoietic stem-cell recipients at a high risk of CMV infection.
Douglas G; Yong MK; Tio SY; Chau M; Prabahran A; Sasadeusz J; Slavin M; Ritchie D; Chee L
Transpl Infect Dis; 2023 Feb; 25(1):e13994. PubMed ID: 36413495
[TBL] [Abstract][Full Text] [Related]
12. Risk factor analysis for cytomegalovirus reactivation under prophylaxis with letermovir after allogeneic hematopoietic stem cell transplantation.
Mizuno K; Sakurai M; Kato J; Yamaguchi K; Abe R; Koda Y; Kataoka K; Mori T
Transpl Infect Dis; 2022 Dec; 24(6):e13904. PubMed ID: 35870130
[TBL] [Abstract][Full Text] [Related]
13. Extended duration letermovir in allogeneic hematopoietic stem cell transplant.
Hinman B; Cox J; Umoru G; Kamble R; Musick W
Transpl Immunol; 2023 Dec; 81():101936. PubMed ID: 37770000
[TBL] [Abstract][Full Text] [Related]
14. Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world experience.
Lin A; Maloy M; Su Y; Bhatt V; DeRespiris L; Griffin M; Lau C; Proli A; Barker J; Shaffer B; Giralt SA; Jakubowski AA; Papadopoulos EB; Papanicolaou GA; Seo SK; Perales MA
Transpl Infect Dis; 2019 Dec; 21(6):e13187. PubMed ID: 31585500
[TBL] [Abstract][Full Text] [Related]
15. Letermovir Prophylaxis for Cytomegalovirus Infection in Children After Hematopoietic Cell Transplantation.
Richert-Przygonska M; Jaremek K; Debski R; Konieczek J; Lecka M; Dziedzic M; Bogiel T; Styczynski J; Czyzewski K
Anticancer Res; 2022 Jul; 42(7):3607-3612. PubMed ID: 35790275
[TBL] [Abstract][Full Text] [Related]
16. Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients.
Douglas CM; Barnard R; Holder D; Leavitt R; Levitan D; Maguire M; Nickle D; Teal V; Wan H; van Alewijk DCJG; van Doorn LJ; Chou S; Strizki J
J Infect Dis; 2020 Mar; 221(7):1117-1126. PubMed ID: 31781762
[TBL] [Abstract][Full Text] [Related]
17. Impact of Primary Letermovir Prophylaxis Versus Preemptive Antiviral Therapy for Cytomegalovirus on Economic and Clinical Outcomes after Hematopoietic Cell Transplantation.
Tan CA; Palen L; Su Y; Li Y; Gennarelli RL; Perales MA; Cohen N; Papanicolaou GA; Shah GL; Seo SK
Transplant Cell Ther; 2024 Jun; ():. PubMed ID: 38838781
[TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus events in high-risk allogeneic hematopoietic-cell transplantation patients who received letermovir prophylaxis.
Chen K; Arbona-Haddad E; Cheng MP; McDonnell AM; Gooptu M; Orejas JL; Timblin K; Silverman E; Al-Hamed R; Soiffer RJ; Hammond SP; Marty FM
Transpl Infect Dis; 2021 Aug; 23(4):e13619. PubMed ID: 33866648
[TBL] [Abstract][Full Text] [Related]
19. Letermovir Prophylaxis Decreases Burden of Cytomegalovirus (CMV) in Patients at High Risk for CMV Disease Following Hematopoietic Cell Transplant.
Johnsrud JJ; Nguyen IT; Domingo W; Narasimhan B; Efron B; Brown JW
Biol Blood Marrow Transplant; 2020 Oct; 26(10):1963-1970. PubMed ID: 32653623
[TBL] [Abstract][Full Text] [Related]
20. Real world experience: Examining outcomes using letermovir for CMV prophylaxis in high-risk allogeneic hematopoietic stem cell patients in the setting of using T-cell depletion as GVHD prophylaxis.
Dwabe S; Hsiao M; Ali A; Rodman J; Savitala-Damerla L; Nazaretyan S; Kimberly Schiff NP; Tam E; Ladha A; Woan K; Chaudhary P; Yaghmour G
Transpl Immunol; 2023 Feb; 76():101769. PubMed ID: 36464218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
